MAIA Updated Analysis: Phase III Study of D-Rd vs Rd for ASCT-Ineligible Newly Diagnosed MM

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
After 4 years of follow-up, addition of daratumumab to lenalidomide/dexamethasone reduced the risk of progression or death by 46% and tripled the rate of MRD negativity.
Format: Microsoft PowerPoint (.ppt)
File Size: 287 KB
Released: December 17, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Related Content

Gain key clinical insights quickly with this short slideset from CCO on the use of PI3K inhibitors in the treatment of follicular lymphoma.

John M. Burke, MD Nathan H. Fowler, MD Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

Downloadable slideset on the current treatment landscape for patients with relapsed and refractory follicular lymphoma, from Clinical Care Options (CCO)

John M. Burke, MD Released: June 17, 2021

Download these expert-selected slides on novel investigational treatments and MRD testing in AML, by Clinical Care Options (CCO)

Eunice S. Wang, MD Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue